Dovitinib Ameliorates Inflammation-Related Diseases by Inhibiting Necroptosis and Ferroptosis

Yingying Lin1, Jianting Feng1, Mingyuan Zhao1

  • 1The School of Basic Medical Sciences, Fujian Medical University, Fuzhou 350004, China.

ACS Chemical Biology
|August 21, 2025
PubMed

Insights

Dovitinib (Dov) effectively inhibits both necroptosis and ferroptosis, two cell death types linked to organ injury and inflammation. This dual-action compound shows potential as a therapeutic for related diseases.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Pharmacology

Background:

  • Dysregulated cell death, including necroptosis and ferroptosis, significantly contributes to organ injury and inflammation.
  • Targeting these cell death pathways is a promising therapeutic strategy for various pathological conditions.

Purpose of the Study:

  • To identify novel inhibitors of necroptosis and ferroptosis.
  • To evaluate the therapeutic potential of identified compounds in disease models.

Main Methods:

  • Screening of a small-molecule compound library to identify dual inhibitors.
  • Investigating the molecular mechanisms of inhibition for necroptosis (via RIPK1) and ferroptosis (via NRF2/HMOX1 axis).
  • Assessing compound efficacy in models of TNF-induced inflammation and concanavalin A-induced acute liver injury.

Main Results:

  • Dovitinib (Dov) was identified as a potent dual inhibitor of necroptosis and ferroptosis.
  • Dov inhibited TNF-induced necroptosis by regulating RIPK1, alleviating systemic inflammation.
  • Dov inhibited ferroptosis by modulating the NRF2/HMOX1 axis and lipid peroxidation, protecting against liver injury.

Conclusions:

  • Dovitinib acts as a dual inhibitor of necroptosis and ferroptosis.
  • Dovitinib presents a potential therapeutic agent or combination therapy for diseases involving these cell death pathways.

Related Concept Videos

Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.8K
Overview of Cell Death01:30

Overview of Cell Death

Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
231
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.6K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K